The Leukemia Research medical journal published results from a study that showed efficacy when treating Acute Myeloid Leukemia (AML).
Great news for the rare disease community!
Onconova Therapeutics announced the publication of results from a Phase 1/2 study of rigosertib intravenous in patients with MDS and MDS which progressed to AML. In the study, rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood counts.
Furthermore, patients who responded to treatment had one year longer survival than non-responders!
AML is a cancer of the blood and bone marrow; “acute” refers to the disease’s rapid progression, while “myelogenous” means it affects a group of white blood cells called the myeloid cells. To learn more about this rare disease, click here.
“The publication of results from this historical study provides support of the relationship between bone marrow blast response and improvement in overall survival in this group of patients with MDS and Acute Myeloid Leukemia, for whom no FDA approved treatments are currently available,” commented Ramesh Kumar, President and CEO of Onconova. “These data are fundamental to the rationale of the ongoing clinical studies in HR-MDS, including INSPIRE, where we are positioned for key milestones, beginning with a pre-planned interim analysis of our INSPIRE pivotal trial in the coming months.”
These early good signs spell hope for better treatment options for this tough form of leukemia!
You can read the full details here.